PRINCETON, N.J. , May 22, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced the pricing of its initial public offering of 9,166,667 shares of...
PRINCETON, N.J. , June 18, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , (NASDAQ: AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari , the Company's Chief Executive...
PRINCETON, N.J. , June 30, 2014 /PRNewswire/ -- Agile Therapeutics, Inc. , (NASDAQ: AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced it has been added to the Russell Microcap Index....
PRINCETON, N.J. , Sept. 2, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Mr....
Twirla (AG200-15) is a Novel Low-Dose Combined Hormonal Contraceptive Patch Designed Using the Company's Proprietary Transdermal Skinfusion ® Technology Confirmatory SECURE Study To Build Upon Data From Previous Phase 3 Studies in Support of the Company's New Drug Application to the U.S....